Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling approach.

ABSTRACT: Visceral leishmaniasis (VL), caused by Leishmania infantum, is an oft-fatal neglected tropical disease. In the absence of an effective vaccine, the control of leishmaniasis relies exclusively on chemotherapy. Due to the lack of established molecular/genetic markers denoting parasite resistance, clinical treatment failure is often used as an indicator. Antimony-based drugs have been the standard antileishmanial treatment for more than seven decades, leading to major drug resistance in certain regions. Likewise, drug resistance to miltefosine and amphotericin B continues to spread at alarming rates. In consequence, innovative approaches are needed to accelerate the identification of antimicrobial drug targets and resistance mechanisms. To this end, we have implemented a novel approach

SUBMITTER: Ibarra-Meneses AV 

PROVIDER: S-EPMC9381709 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature